On July 16, 2024, Apollomics Inc., a clinical-stage biopharmaceutical company, announced that it has been granted a 180-day extension by The Nasdaq Stock Market LLC to meet the minimum bid price requirement for continued listing on The Nasdaq Capital Market. The company must now ensure that the closing bid price of its common stock is at least $1.00 per share for a minimum of ten consecutive business days before January 13, 2025, to regain compliance with Nasdaq Listing Rule 5550(a)(2). Failure to meet this requirement may lead to delisting, although the company can appeal such a decision to a Nasdaq Hearings Panel. Apollomics is actively monitoring its share price and exploring options to regain compliance. The company specializes in developing oncology drug candidates, including vebreltinib for non-small cell lung cancer and uproleselan for acute myeloid leukemia, which are in various stages of clinical trials.

On July 16, 2024, Apollomics Inc., a clinical-stage biopharmaceutical company, announced that it has been granted a 180-day extension by The Nasdaq Stock Market LLC to meet the minimum bid price requirement for continued listing on The Nasdaq Capital Market. The company must now ensure that the closing bid price of its common stock is at least $1.00 per share for a minimum of ten consecutive business days before January 13, 2025, to regain compliance with Nasdaq Listing Rule 5550(a)(2). Failure to meet this requirement may lead to delisting, although the company can appeal such a decision to a Nasdaq Hearings Panel. Apollomics is actively monitoring its share price and exploring options to regain compliance. The company specializes in developing oncology drug candidates, including vebreltinib for non-small cell lung cancer and uproleselan for acute myeloid leukemia, which are in various stages of clinical trials.